OncoMatch/Clinical Trials/NCT05765084
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Is NCT05765084 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Dendritic cell vaccination and Atezolizumab for malignant pleural mesothelioma.
Treatment: Dendritic cell vaccination · Atezolizumab · Platinum/pemetrexed based chemotherapy — In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum/pemetrexed-based first-line chemotherapy for the treatment of epitheloid malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with atezolizumab and WT1/DC vaccination is feasible and safe, has clinical activity and enables the induction of mesothelioma-specific immune responses in patients with MPM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Mesothelioma
Disease stage
Required: Stage I, II, III, IV
Performance status
WHO 0–1
Prior therapy
Cannot have received: any treatment for MPM
Prior treatment for MPM
Cannot have received: CD137 agonist
Prior treatment with CD137 agonists
Cannot have received: immune checkpoint blockade therapy
Prior treatment with immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (1500/μL) without G-CSF; lymphocyte count ≥ 0.5 x 10^9/L (500/μL); platelet count ≥ 100 x 10^9/L (100,000/μL) without transfusion; hemoglobin ≥ 90 g/L (9 g/dL), may be transfused
Kidney function
creatinine ≤ 1.5 x ULN
Liver function
AST, ALT, ALP ≤ 2.5 x ULN (≤ 5 x ULN with liver/bone metastases); total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN with Gilbert disease); albumin ≥ 25 g/L (2.5 g/dL)
Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained at the time of screening: ... (see full criteria above)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05765084 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage I or II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages